Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 178

Sort by

Sort Order Select

Journal Articles

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD

Pamela Allen, MD MSc, Hatice Savas, MD, Andrew M. Evens, DO,MSc, Barbara Pro, MD, Reem Karmali, MD, Brett Alan Palmer, BS, Eric Mou, MD, Jeffrey Bearden, BA, Denise M Scholtens, PhD, Gary Dillehay, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 235.

https://doi.org/10.1182/blood-2019-123906

Published: 2019

Journal Articles

PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, MD, Robert W. Chen, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, Matthew Mei, MD, Leslie L. Popplewell, MD FRCPA, Auayporn P. Nademanee, MDBS, Liana Nikolaenko, MD, Kathryn McBride, Ricardo Ortega, Joo Y. Song, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Stephen J Forman, MD, Hun Ju Lee, MD

Blood (2019) 134 (Supplement_1): 239.

https://doi.org/10.1182/blood-2019-123162

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

Zhijian Cao, MD, Jun Ma, MD PhD

Blood (2019) 134 (Supplement_1): 5478.

https://doi.org/10.1182/blood-2019-126686

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Pallavi Mehta, MD DM, Neha Yadav, BDS , MBA, Mohan Bhaarat, Sumeet Prakash Mirgh, MBBS, MDDM, Vishvdeep Khushoo, MBBS, MDDM, Shinto Francis Thekuddan, MBBS, MDDM, Narendra Agrawal, MD DM, Rayaz Ahmed, MDDM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 5572.

https://doi.org/10.1182/blood-2019-131674

Published: 2019

Journal Articles

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Jonathan Pan, MD, Sushil Ghimire, MD, Tingting Zhan, PhD, Onder Alpdogan, MD, Andrew E. Chapman, DO, Matthew Carabasi, MD, Ubaldo Martinez-Outschoorn, MD, Lewis J. Rose, MD, Michael Ramirez, MD, John L Wagner, MD, Barbara Pro, MD, Mark A. Weiss, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD

Blood (2019) 134 (Supplement_1): 5318.

https://doi.org/10.1182/blood-2019-125836

Published: 2019

Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Blood (2019) 134 (Supplement_1): 5320.

https://doi.org/10.1182/blood-2019-124102

Published: 2019

Journal Articles

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Blood (2019) 134 (Supplement_1): 4161.

https://doi.org/10.1182/blood-2019-127923

Published: 2019

Journal Articles

Adverse Events during Induction Therapy in Pediatric Acute Lymphoblastic Lymphoma (ALL)

Zachary West, BS, Kristen Allen, MPH, Caitlin Monroe, MPH, Sharon M. Castellino, MD MSc, Tamara P. Miller, MDMSc

Blood (2019) 134 (Supplement_1): 5809.

https://doi.org/10.1182/blood-2019-131873

Published: 2019

Journal Articles

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis

Larysa Sanchez, MD, Heather J Landau, MD, Cara A. Rosenbaum, MD, Alex Abrahams, Cindy Chin, Brielle Liotta, BS, Natalie Agudo, RN, Sheetal Ramnath, Elizabeth Hoover, BS, Hafsa Rahman, Umut Ozbek, PhD, Oscar B Lahoud, MD, Hani Hassoun, MD, Keren Osman, MD

Blood (2019) 134 (Supplement_1): 3128.

https://doi.org/10.1182/blood-2019-126023

Published: 2019

Journal Articles

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Yuankai Shi, MD, Lin Gui, MD, Junning Cao, MD, Huilai Zhang, MD, Jun Zhu, MD PhD, Dongmei Ji, MD PhD, Qian Fan, MD, Yuqin Song, MD PhD, Weina Shen, MM, Guiying Bai, MM, Ming-Zhe Han, MD, Shiyu Jiang

Blood (2019) 134 (Supplement_1): 2840.

https://doi.org/10.1182/blood-2019-128078

Published: 2019

Journal Articles

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Marc Schwartz, MD, Lloyd E. Damon, MD, Deepa Jeyakumar, MD, Caitlin L. Costello, MD, Dimitrios Tzachanis, MD PhD, Gary J. Schiller, MD, Jesika Reiner, MPH, Matthew J. Wieduwilt, MD PhD

Blood (2019) 134 (Supplement_1): 3880.

https://doi.org/10.1182/blood-2019-131061

Published: 2019

Journal Articles

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

Sameem Abedin, MD, Guru Subramanian Guru Murthy, MBBS, Lyndsey Runaas, MD, Laura C. Michaelis, MD, Ehab L. Atallah, MD, Mehdi Hamadani, MD, Alexandra M. Harrington, MDMT(ASCP), Karen Carlson, MD

Blood (2019) 134 (Supplement_1): 2605.

https://doi.org/10.1182/blood-2019-122487

Published: 2019

Journal Articles

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Jacqueline S Garcia, MD, Helen I. Gandler, Geoffrey Fell, MS, Ashlee J. Fiore, Donna S Neuberg, ScD, Adrienne Anderson, Kelsey O'Day, Marlise Luskin, MDMS, Martha Wadleigh, MD, Eric S. Winer, MD, Ilene Galinsky, Daniel J. DeAngelo, MD, David A. Frank, MD PhD, Richard M. Stone, MD

Blood (2019) 134 (Supplement_1): 2549.

https://doi.org/10.1182/blood-2019-126224

Published: 2019

Journal Articles

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Matthew Mei, MD, Saro H. Armenian, DO, MPH, Justin Darrah, MD, Liana Nikolaenko, MD, Robert W. Chen, MD, Lacolle Peters, Neena Kennedy, Steven Rosen, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 759.

https://doi.org/10.1182/blood-2019-123163

Published: 2019

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Steven M. Horwitz, MD, Neha Mehta-Shah, MD, Barbara Pro, MD, Eric D Jacobsen, MD, Carla Casulo, Jonathan E. Brammer, MD, Jeff Haney, Hagop Youssoufian, MD, David T. Weaver, PhD, Michael Baglio, PharmD, Jasminder Soto, Narayana Narasimhan, Jasmine Zain, MD

Blood (2019) 134 (Supplement_1): 1567.

https://doi.org/10.1182/blood-2019-121401

Published: 2019

Journal Articles

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Alexandra Savell, BS, Karen Francoeur, RN, Mark Choiniere, BA, Josie Montegaard, NP, Jacob D. Soumerai, MD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD

Blood (2019) 134 (Supplement_1): 1763.

https://doi.org/10.1182/blood-2019-127343

Published: 2019

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Veronika Bachanova, MD PhD, David H. McKenna, MD, Xianghua Luo, PhD, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD MS, Erica D. Warlick, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Guy Brachya, PhD, Tony Peled, MSc, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 777.

https://doi.org/10.1182/blood-2019-130476

Published: 2019

Journal Articles

Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

Paolo Caimi, MD, Deepa Jagadeesh, MDMPH, Kirsten Marie Boughan, DO, Robert M. Dean, MD, Brenda Cooper, MD, Brad Pohlman, MD, Molly M Gallogly, MDPhD, Sarah L. Ondrejka, DO, Erika Moore, MD, Kwadwo Asare Oduro, MDPhD, Eric D. Hsi, MD, Marcos de Lima, MD, Brian T. Hill, MD PhD

Blood (2018) 132 (Supplement 1): 397.

https://doi.org/10.1182/blood-2018-99-115587

Published: 2018

NARROW

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD

PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma

Efficacy and Safety of Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Adverse Events during Induction Therapy in Pediatric Acute Lymphoblastic Lymphoma (ALL)

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Safety and Efficacy of Venetoclax Combined with Rituximab, Ifosfamide, Carboplatin and Etoposide Chemoimmunotherapy (VICER) for Treatment of Relapsed Diffuse Large B Cell Lymphoma: Results from the Phase 1 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only